[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619245":3},{"organization":4,"outcomesModule":7,"designInfo":25,"detailedDescription":11,"studyPopulation":11,"armGroups":36,"interventions":49,"overallOfficials":57,"centralContacts":61,"locations":69,"responsibleParty":84,"collaborators":11,"id":86,"slug":11,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":11,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":11,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":11,"overallStatus":72,"whyStopped":11,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants with Adverse Events (AEs)",null,"Up to approximately 3 months",[14,17,20,22],{"measure":15,"description":11,"timeFrame":16},"Serum concentration of RO7875913","Up to Day 76",{"measure":18,"description":11,"timeFrame":19},"Percentage of Participants with Anti-Drug Antibodies (ADAs) to RO7875913 at Baseline and with ADAs to RO7875913 During the Treatment Period","Baseline, Up to Day 76",{"measure":21,"description":11,"timeFrame":12},"Recommended Phase II Dose (RP2D) of RO7875913",{"measure":23,"description":11,"timeFrame":24},"Observed Value of Pharmacodynamic Markers","Baseline, up to approximately 3 months",{"allocation":26,"interventionModel":27,"interventionModelDescription":11,"primaryPurpose":28,"observationalModel":11,"timePerspective":11,"maskingInfo":29},"RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":30,"maskingDescription":11,"whoMasked":31},"QUADRUPLE",[32,33,34,35],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[37,43],{"label":38,"type":39,"description":40,"interventionNames":41},"RO7875913","EXPERIMENTAL","Participants will receive RO7875913.",[42],"Drug: RO7875913",{"label":44,"type":45,"description":46,"interventionNames":47},"Placebo","PLACEBO_COMPARATOR","Participants will receive Placebo.",[48],"Drug: Placebo",[50,54],{"type":51,"name":38,"description":52,"armGroupLabels":53,"otherNames":11},"DRUG","Participants will receive RO7875913 as per the schedule described in the protocol.",[38],{"type":51,"name":44,"description":55,"armGroupLabels":56,"otherNames":11},"Participants will receive placebo as per the schedule described in the protocol.",[44],[58],{"name":59,"affiliation":5,"role":60},"Clinical Trials","STUDY_DIRECTOR",[62,67],{"name":63,"role":64,"phone":65,"phoneExt":11,"email":66},"Reference Study ID Number: GO46451 https:\u002F\u002Fforpatients.roche.com\u002F No email attachments.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":68,"role":64,"phone":11,"phoneExt":11,"email":11},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[70],{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":76,"countryCode":77,"cosmosGeoPoint":78,"geoPoint":83,"contacts":11},"New Zealand Clinical Research - Christchurch","RECRUITING","Christchurch","Canterbury","8011","New Zealand","NZ",{"type":79,"coordinates":80},"Point",[81,82],172.63333,-43.53333,{"lat":82,"lon":81},{"type":85,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100619245",false,"NCT07342114","A Dose-Escalation Study of RO7875913 in Healthy Participants","A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers","Inclusion Criteria:\n\n* Agreement to adhere to the contraception requirements\n* Body weight \\> 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg\u002Fm\\^2)\n\nExclusion Criteria:\n\n* Positive test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen\n* History of any malignancy\n* Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders\n* Known allergy or hypersensitivity to any component of the RO7875913 formulation\n* Treatment with investigational biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug\n* Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug\n* Treatment with any immunosuppressive medication within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug",true,"ALL","18 Years","65 Years",{"count":97,"type":98},40,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.",[104],"Healthy Volunteers","2026-06-19",{"date":107,"type":108},"2026-06-24","ACTUAL",{"date":110,"type":108},"2026-03-11",{"date":112,"type":98},"2026-12-31",{"name":5,"class":6},1]